Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Takii & Co. Ltd. operates a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The company is currently responding to 1 pending office action. Prosecution is handled by 1 distinct examiner and is situated within 1 distinct art unit. This indicates a very narrow administrative footprint for the company's active patent matters.
The busiest examiner for this portfolio is MEADOWS, CHRISTINA L, who is currently managing 1 busiest examiner pending office action. Because the total number of pending office actions is 1, this specific examiner is responsible for the company's entire active workload. The concentration in 1 distinct art unit suggests that the subject matter remains within a specific biological or pharmaceutical sub-discipline.
For practitioners, the presence of 1 distinct examiner means that prosecution strategy can be tailored specifically to the tendencies of MEADOWS, CHRISTINA L. The active filing serves as the primary focus for the company's current intellectual property maintenance. This streamlined distribution of examiners and art units minimizes the complexity of managing multiple simultaneous legal deadlines.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MEADOWS, CHRISTINA L | 1 | 76.1% | +23.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18703152 | EUSTOMA PLANT WITH EUSTOMA FUSARIUM WILT RESISTANCE | MEADOWS, CHRISTINA L | 66d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18703152 | EUSTOMA PLANT WITH EUSTOMA FUSARIUM WILT RESISTANCE | MEADOWS, CHRISTINA L | 66d overdue |
| Art Unit | Apps |
|---|---|
| 1663 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18703152 | EUSTOMA PLANT WITH EUSTOMA FUSARIUM WILT RESISTANCE | MEADOWS, CHRISTINA L | 1663 | §101§112 | Non-Final OA | 66d overdue | Pending | Apr 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial